Key Companies in the Veterinary Medicine Market

Why Is the Veterinary Medicine Market Expanding?

The Global Veterinary Medicine Market is expected to increase from USD 46.48 billion in 2025 to USD 95.63 billion by 2035, at a CAGR of 7.48% during the forecast period of 2026-2035. According to Market Research Future (MRFR), the key demand drivers are threefold and equally significant: the rising global burden of zoonotic and chronic animal diseases, the quick transition from antibiotic treatment to vaccine-first preventive solutions, and the growing premiumization of companion animal care, with pet owners increasingly considering veterinary pharmaceuticals as a necessity, not an expense.

The convergence of regulatory antibiotic stewardship such as the FDA’s Guidance for Industry #263 and EU Veterinary Medicinal Products Regulation 2019/6 with breakthrough biologics innovation is substantially changing competitive economics. Legacy small-molecule generics, with gross margins of 20 to 30 percent, are being displaced by recombinant vaccines and monoclonal antibody treatments, with margins of 40 to 60 percent. Globally, investors invested more than USD 2.8 billion in venture capital into companion animal medications in 2024, with a bet on biologics driving the next wave of innovation. North America was the leading region, with an estimated 38.1% share of 2025 revenue, driven by the USD 36 billion companion-animal care economy in the United States. Asia-Pacific is the fastest-growing region, with a projected 10.80% CAGR, driven by rising pet adoption in China and India and industrialized livestock veterinary care in Southeast Asia.

Why These Companies Are Leading the Market?

MRFR identifies four structural factors that define category leadership in the Veterinary Medicine Market: vertically integrated R&D-to-manufacturing capabilities spanning parasiticides, vaccines, and biologics; geographic scale with direct regulatory dossier submission capabilities across the FDA, EMA, and APVMA; diagnostic-to-prescription ecosystem integration that creates pull-through demand for proprietary therapeutics; and disciplined M&A strategy to acquire recombinant platform technologies and fill species-specific portfolio gaps.

Top 10 Global Veterinary Medicine Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading veterinary medicine companies globally, evaluated on the basis of revenue performance, geographic presence, product breadth, technology strategy, innovation investment, and species coverage. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of July 2026.

Detailed Company Profiles

1. Zoetis Inc. | NYSE: ZTS | Parsippany, New Jersey, USA

Company Overview. Zoetis is the world’s largest pure-play animal health company, operating across medications, vaccines, diagnostics and genetics. The company’s strategy to vertically integrate diagnostics — with its 2018 acquisition of Abaxis and subsequent growth of its reference-laboratory network — generates a data feedback loop that in-clinic testing systems can’t match. Zoetis reported total sales of USD 9.467 billion for fiscal year 2025, with 2% reported growth and 3% operational growth, according to the company's SEC Form 10-K filing. U.S. revenue was USD 5.097 billion (54% of total), with a gross margin of 83.5%. International revenue was USD 4.254 billion (45% of total).

2. Boehringer Ingelheim Animal Health | Private (family-owned) | Ingelheim, Germany

Company Overview. Boehringer Ingelheim Animal Health is the animal health section of family-owned pharmaceutical group Boehringer Ingelheim GmbH, founded in 1885. Publicly traded competitors are under pressure to provide quarterly returns, while Boehringer’s family ownership allows years of steady resource deployment to vaccine manufacturing facilities – a strategic patience that no listed counterpart can match. The division manages the world’s largest pure-play animal health vaccine portfolio, covering live attenuated, inactivated and recombinant platforms in cattle, swine, poultry and companion species. However, the parent firm does not separately report revenues of the Animal Health subsidiary.

3. Merck Animal Health (MSD) | NYSE: MRK (segment) | Madison, New Jersey, USA

Company Overview. About Merck Animal Health Merck Animal Health is the global animal health business unit of Merck & Co., Inc. (known as MSD outside the United States and Canada) and a leader in the veterinary medicine industry with vaccines, biologics, medicines, and intelligence services. According to the parent company’s SEC 10-K filing, the division’s full-year 2024 sales were USD 5.877 billion, up 4% reported and 8% excluding foreign exchange. The company’s leading parasiticide franchise BRAVECTO (fluralaner) achieved USD 1.1 billion in 2024 sales (+6% reported, +8% ex-FX) and demonstrated the long-term recurring revenue strength of long-acting companion animal formulations.

4. Elanco Animal Health | NYSE: ELAN | Greenfield, Indiana, USA

Company Overview. Elanco Animal Health is a worldwide animal health company that was founded through the 2019 spin-off of Eli Lilly and Company, and further altered by the 2020 acquisition of Bayer Animal Health. According to its SEC Form 10-K filings, the business recorded total revenue of USD 4.439 billion for fiscal year 2024 and USD 4.715 billion for fiscal year 2025, reflecting 6% reported growth year-over-year. Elanco’s strategic inflection point in 2024 was the July selling of its aqua business to Merck Animal Health for USD 1.294 billion – a move that eliminated a lower-margin area while producing cash utilized to reduce debt. The reduced portfolio focuses on Pet Health (USD 2.300B, 49% of FY2025 revenue) and Farm Animal (USD 2.362B, 50% of FY2025 revenue), with innovation revenue of USD 461 million in 2024 and guidance raised to USD 640–720 million for 2025.

5. IDEXX Laboratories | NASDAQ: IDXX | Westbrook, Maine, USA

Company Overview. IDEXX Laboratories is not a pharmaceutical manufacturer but a leading diagnostic platform provider that participates in the veterinary medicine business through test volume and software integration that creates prescription pull-through for partner and proprietary therapies. The company’s SEC 10-K filing indicated that Companion Animal Group (CAG) income from operations was USD 1.26 billion, and the total revenue for fiscal year 2025 was USD 4.33 billion. IDEXX’s strategic moat is its cloud-linked diagnostic ecosystem, the Procyte One hematology analyzer with AI-assisted cell classification (launched Sept. 2023) and the VetConnect PLUS software platform combining in-clinic test results with reference-lab validation and auto-generated treatment recommendations.

6. Virbac | Euronext: VIRP | Carros, France

Company Overview. Virbac is a mid-cap global animal health firm based in Carros, France, with a strategic focus on companion animal specialty pharmaceuticals and dental, dermatological and vaccine portfolios. In its audited annual results published in March 2026, the company recorded full-year 2025 revenue of EUR 1.465 billion (USD ~1.58 billion), showing +7.9% organic growth at constant exchange rates and scope. Virbac’s differentiation is through its “Essentials” product strategy – a portfolio of 61% of sales in market-leading or potential market-leading goods geared for global distribution with higher gross margins. In December 2025, Virbac purchased Thyronorm (EUR 107.8 million), a specialist medication for feline hyperthyroidism, which affects more than 10% of senior cats, estimated to be accretive from Year 1.

7. Dechra Pharmaceuticals | Private (EQT-owned) | Northwich, United Kingdom

Company Overview. Dechra Pharmaceuticals is a global specialist veterinary pharmaceutical firm, specialising in endocrinology, pain management, dermatology and equine treatments. In 2023, the firm was acquired by EQT Partners and LongStone Capital and delisted from the London Stock Exchange, moving from public to private control. This privatization eliminated quarterly earnings pressures and provided management the freedom to pursue long-term portfolio optimization, including divestiture of non-core product lines and growth in the US specialty veterinary channel, free from short-term shareholder scrutiny. Dechra does not release audited financials post-acquisition; MRFR estimates the annual revenues at GBP 600–700 million based on pre-acquisition disclosures and industry comparisons.

8. Vetoquinol | Euronext: VETO | Lure, France

Company Overview. Vetoquinol is an independent pure-play animal health firm listed on Euronext Paris, focusing on veterinary medicines and non-medicated solutions for farm animals (cattle, pigs) and companion animals (dogs, cats). In its audited annual results issued in March 2026, the company recorded full-year 2025 sales of EUR 525.7 million, up +0.2% at constant exchange rates (-2.5% reported owing to currency headwinds). Essential products achieved EUR 334.5 million (+4.1% CER) and now represent 64% of overall sales (vs. 61% in 2024). The company shows good financial discipline: EBITDA of EUR 113.9 million (21.7% of sales), EBIT before amortization of EUR 91.5 million (17.4% of sales), and a net result of EUR 57.3 million (10.9% of sales).

9. Phibro Animal Health | NASDAQ: PAHC | Teaneck, New Jersey, USA

Company Overview. Phibro Animal Health is a diversified animal health and mineral nutrition company focused on medicated feed additives (MFAs), nutritional specialties, and vaccines for livestock production. For fiscal year 2024, the company recorded total net sales of USD 1.02 billion, with USD 796 million attributable to the Animal Health sector, per its SEC 10-K filing. Phibro's approach is unique among the top-10 competitors: instead of chasing companion animal premiumization, the firm focuses on production-animal efficiency -- MFAs that enhance feed conversion, vaccines that reduce mortality, and mineral supplements that optimize growth rates. This livestock-centric business exposes Phibro to commodity protein price cycles, but also builds deep relationships with integrated poultry and swine producers who care more about cost-per-kilogram data than brand loyalty.

10. Ceva Santé Animale | Private | Libourne, France

Company Overview. Ceva Santé Animale is the 5th largest animal health firm in the world by sales and the largest privately held pure-play and vet-led enterprise with a focus on preventative medicine. The company said it generated 2024 turnover of EUR 1.77 billion (USD ~1.91 billion), after growing sales fourteenfold since being founded in 1999, according to company disclosures. What distinguishes Ceva strategically is its focus on preventative medicine — vaccinations, animal welfare products and reproductive biologics — rather than therapeutic drugs. The company has also invested in companion animal gene therapy and is a leader in platform innovation, being the first veterinary pharmaceutical company to develop and sell an innovative nucleotide vaccine.

M&A Activity Tracker (2018–2025)

The Veterinary Medicine Market has experienced transformative consolidation as operators pursued inorganic growth to capture biologics capabilities, expand species coverage, and rationalize manufacturing footprints. Market Research Future tracks the following verified, named transactions directly relevant to the veterinary medicine market.

Key Trend

According to MRFR study, the prominent M&A theme in the veterinary medication industry is species-portfolio gap-filling. Merck’s acquisition of Elanco’s aqua business closed the final significant species gap in its portfolio, while Elanco’s sale of the same business helped streamline its emphasis on higher-margin companion and farm animal biologics. A similar theme is the privatization of mid-cap specialty pharmaceutical assets, exemplified by Dechra's 2023 take-private by EQT and Virbac's programmatic “Essentials” acquisitions, highlighting private-equity conviction that the fragmentation of veterinary medicine provides rollup opportunities for targeted, margin-accretive consolidation.

R&D Investment & Innovation Signals

R&D and technology investment across the Veterinary Medicine Market has accelerated as operators invest in mRNA vaccine platforms, monoclonal antibody therapeutics, AI-enabled diagnostics, and precision livestock nutrition — addressing the primary competitive constraints of antibiotic-regulatory pressure, biologics cost barriers, and veterinarian workforce shortages that define market differentiation.

• Zoetis (2025): USDA conditional license for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus for use in hens in the U.S. and Canada – validates platform-technology migration from human to animal health and quick strain update for fast-mutating pathogens. Revenue for FY2025 was $9.467 billion with U.S. gross margin of 83.5%.

• Boehringer Ingelheim: Maintains the world’s biggest pure-play animal health vaccination portfolio including live attenuated, inactivated and recombinant platforms. It is the first veterinary pharmaceutical company to develop and commercialize a breakthrough nucleotide vaccination and has invested in gene therapy for companion animals.

• Elanco Animal Health (2024–2025): Launched Credelio Quattro (monthly all-in-one parasiticide for dogs covering heartworm, fleas, ticks, and intestinal worms) and achieved penetration of Zenrelia in 8,000+ US clinics (~30% of target market). FY2025 revenue increased to USD4,715 million (+6% reported), and net leverage declined to 3.6x adjusted EBITDA.

• IDEXX Laboratories (September 2023): Launched AI-assisted cell classification on Procyte One hematology analyzer, increasing the accuracy of point-of-care diagnostics and decreasing the workload for veterinary technicians — a workflow improvement that improves test volumes and generates 20-30 percent better attach rates for pharmaceuticals in linked clinics.

• Merck Animal Health (July 2024): Acquires Elanco aqua business for USD 1.294 billion and adds capabilities for warm-water and cold-water species and immediately positions Merck as the global aqua health leader – transforming the company from a terrestrial-animal health company into a full-spectrum aquatic and terrestrial platform. FY2024 Animal Health net sales: USD 5.877 billion.